lafutidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
histamine-H2-receptor antagonists, cimetidine derivatives	1537	206449-93-6

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

FRG 8813
FRG-8813
lafutidine
laflutidine
protecadin

histamine H(2)-receptor antagonist used as an antiulcer drug

Molecular weight: 431.55
Formula: C22H29N3O4S
CLOGP: 1.80
LIPINSKI: 0
HAC: 7
HDO: 1
TPSA: 84.67
ALOGS: -3.25
ROTB: 11

Drug dosage:

Dose	Unit	Route
20	mg	O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	63.03	37.02	27	532	116095	63372368
Interstitial lung disease	38.83	37.02	16	543	61892	63426571

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	32.52	31.30	22	579	119695	34836635

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Platelet count decreased	87.34	27.35	49	1301	194615	79548423
Interstitial lung disease	63.36	27.35	33	1317	112567	79630471
Neutrophil count decreased	37.54	27.35	22	1328	93937	79649101
White blood cell count decreased	36.26	27.35	28	1322	188260	79554778
Hepatic function abnormal	28.87	27.35	17	1333	73090	79669948

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02BA08	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists
MeSH PA	D000897	Anti-Ulcer Agents
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006635	Histamine H2 Antagonists
MeSH PA	D018377	Neurotransmitter Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Gastro-esophageal reflux disease with esophagitis	indication	266433003

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.06	acidic
pKa2	7.57	Basic
pKa3	2.04	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D01131	KEGG_DRUG
C0172827	UMLSCUI
CHEBI:31759	CHEBI
CHEMBL1742461	ChEMBL_ID
DB12770	DRUGBANK_ID
C076948	MESH_SUPPLEMENTAL_RECORD_UI
5282136	PUBCHEM_CID
7173	INN_ID
49S4O7ADLC	UNII

Pharmaceutical products:

None